StockData
IBONYSEPharmaceutical PreparationsFiscal year ends December 31

IMPACT BIOMEDICAL INC.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026
$3.06+0.38 (+14.18%)

Close on Oct 19, 2026

Market cap
$329.93M
P/E (TTM)
–
Dividend yield
–

SEC filings

32 of Impact Biomedical's most recent filings on SEC EDGAR

DocumentFormPeriodFiledSource
Current report8-KSep 23, 2026Oct 9, 2026SEC EDGAR
Current report8-KSep 16, 2026Sep 17, 2026SEC EDGAR
Current report8-KSep 14, 2026Sep 15, 2026SEC EDGAR
Quarterly report10-QJun 30, 2026Aug 7, 2026SEC EDGAR
Quarterly report10-QMar 31, 2026May 12, 2026SEC EDGAR
Annual report10-KDec 31, 2025Mar 11, 2026SEC EDGAR
Current report8-KFeb 27, 2026Mar 4, 2026SEC EDGAR
Quarterly report10-QSep 30, 2025Nov 7, 2025SEC EDGAR
Current report8-KNov 5, 2025Nov 6, 2025SEC EDGAR
Current report8-KOct 24, 2025Oct 27, 2025SEC EDGAR
Proxy statementDEF 14ASep 22, 2025Sep 22, 2025SEC EDGAR
Quarterly report10-QJun 30, 2025Aug 14, 2025SEC EDGAR
Current report8-KJul 21, 2025Jul 28, 2025SEC EDGAR
Current report8-KJun 23, 2025Jun 23, 2025SEC EDGAR
Quarterly report10-QMar 31, 2025May 14, 2025SEC EDGAR
Current report8-KApr 3, 2025Apr 3, 2025SEC EDGAR
Annual report10-KDec 31, 2024Mar 28, 2025SEC EDGAR
Current report8-KMar 24, 2025Mar 28, 2025SEC EDGAR
Current report8-KMar 11, 2025Mar 13, 2025SEC EDGAR
Current report8-KJan 29, 2025Jan 29, 2025SEC EDGAR
Quarterly report10-QSep 30, 2024Nov 12, 2024SEC EDGAR
Current report8-KNov 4, 2024Nov 4, 2024SEC EDGAR
Current report8-KOct 3, 2024Oct 8, 2024SEC EDGAR
Current report8-KSep 16, 2024Sep 17, 2024SEC EDGAR
Quarterly report10-QJun 30, 2024Aug 13, 2024SEC EDGAR
Current report8-KJun 6, 2024Jun 7, 2024SEC EDGAR
Quarterly report10-QMar 31, 2024May 10, 2024SEC EDGAR
Annual report10-KDec 31, 2023Feb 20, 2024SEC EDGAR
Current report8-KJan 18, 2024Jan 22, 2024SEC EDGAR
Quarterly report10-QSep 30, 2023Nov 13, 2023SEC EDGAR
Current report8-KOct 31, 2023Nov 6, 2023SEC EDGAR
Quarterly report10-QJun 30, 2023Oct 5, 2023SEC EDGAR